CRNA.OL Circio Holding ASA
- Market cap
- NOK 2.91B
- P/E
- -
- P/B
- 5.55x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is CRNA.OL undervalued?
Graham numberThe Graham number of Circio Holding ASA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Circio Holding ASA fundamental analysis
No fundamental analysis for Circio Holding ASA yet.
Circio Holding ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for th…
Full company profileCircio Holding ASA financial statements
Circio Holding ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 624K | 0.00 | 10.0M | 123K | 0.00 | 0.00 |
| Operating Income | -104M | -95.6M | -494M | -100.0M | -42.5M | -41.1M |
| EBITDA | - | - | -97.7M | -108M | 57.6M | -45.7M |
| Net Income | -108M | -98.0M | -433M | -113M | 57.5M | -45.9M |
| EPS | -27 | -16 | -64 | -15 | 0.79 | -0.31 |
| Balance Sheet | ||||||
| Total Assets | 521M | 565M | 100M | 25.7M | 21.8M | 10.8M |
| Total Liabilities | 148M | 148M | 97.8M | 124M | 34.3M | 23.2M |
| Shareholders' Equity | 373M | 418M | 2.57M | -98.5M | -12.5M | -12.5M |
| Cash & Short-term Investments | 119M | 178M | 63.0M | 20.8M | 17.8M | 6.04M |
| Cash Flow | ||||||
| Operating Cash Flow | -111M | -85.4M | -109M | -89.2M | -40.5M | -45.8M |
| Capital Expenditure | 70.0K | 0.00 | 4.96M | 193K | 189K | 0.00 |
| Free Cash Flow | - | -85.4M | -114M | -89.4M | -40.7M | -45.8M |
| Ratios | ||||||
| ROE | -29.0% | -23.5% | -16,870.5% | - | - | - |
| ROA | -20.8% | -17.3% | -431.1% | -439.3% | 263.5% | -426.8% |
| Net Profit Margin | -17,327.9% | - | -4,328.1% | -91,822.0% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Circio Holding ASA dividends
Circio Holding ASA has not paid dividends in the last 6 fiscal years.
Last stock split: 1:30 on Oct 4, 2023.
Who owns Circio Holding ASA
- Insiders 30.07%
- Institutions 5.11%
- Public & others 64.83%
- Shares outstanding 291M
- Free float 222M
Circio Holding ASA company profile
- Company name
- Circio Holding ASA
- Ticker
- CRNA.OL
- ISIN
- NO0013033795
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Tordenskiolds gate 2, Oslo, Norway, 0160
- Phone
- 47 929 51 788
- Website
- circio.com
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.
Circio Holding ASA management
8- Dr. Erik Digman WiklundChief Executive Officer
- Dr. Lubor Gaal Ph.D.Chief Financial Officer · born 1969
- Mr. Ola MelinChief Operating Officer
- Dr. Thomas Birkballe HansenChief Technology Officer
- Dr. Victor Levitsky M.D., Ph.D.Chief Scientific Officer
- Mr. Jon Amund Eriksen M.Sc.Special Advisor
- Prof. Gustav Gaudernack Ph.D.Chief Scientific Adviser
- Dr. Peter Skorpil Ph.D.Vice President of Business Development